What is the price of Citius Pharmaceuticals, Inc. (CTXR)

The price of Citius Pharmaceuticals, Inc. (CTXR) is $0.5701

What is the market cap of Citius Pharmaceuticals, Inc. (CTXR)

The market cap of Citius Pharmaceuticals, Inc. (CTXR) is $6.37M

Citius Pharmaceuticals, Inc. (CTXR) P/B Ratio

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Year	P/B Ratio	Change
Not enough data for the provided dates.

Year

P/B Ratio

Change

Not enough data for the provided dates.

Company	P/B Ratio	P/B Ratio Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.4612	-	BE

Company

P/B Ratio

P/B Ratio Difference

Country